Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Allon Therapeutics |
---|---|
Information provided by: | Allon Therapeutics |
ClinicalTrials.gov Identifier: | NCT00404014 |
The primary objective is to compare mild cognitive impairment in the AL-208 group with the placebo group at 14 +
Condition | Intervention | Phase |
---|---|---|
Mild Cognitive Impairment |
Drug: AL-208 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Study Designed to Evaluate the Safety, Tolerability, and Effect of a Single, Rising Dose of Intravenous AL-208, Followed by a Placebo-Controlled, Double-Blind, Parallel-Group Evaluation of a Single Dose of AL-208, on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery. |
Ages Eligible for Study: | 50 Years to 79 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Elena Matthews, MD | Medical Monitor on behalf of Allon Therapeutics |
Responsible Party: | Allon Therapeutics Inc. ( Director, Clinical Operations ) |
Study ID Numbers: | AL 208-201 |
Study First Received: | November 24, 2006 |
Last Updated: | September 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00404014 History of Changes |
Health Authority: | United States: Food and Drug Administration; Canada: Health Canada |
MCI following CABG surgery |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Dementia Cognition Disorders Delirium |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Cognition Disorders |